MIG Antibody (A-9): sc-514138

MIG Antibody (A-9) is a mouse monoclonal IgG2a kappa light chain antibody that detects MIG protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-MIG antibody (A-9) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. MIG, also known as monokine induced by interferon-gamma or chemokine (C-X-C motif) ligand 9 (CXCL9), plays a crucial role in T cell trafficking and has been shown to inhibit angiogenesis while exhibiting thymus-dependent anti-tumor effects. MIG is secreted and primarily functions in the immune response, particularly in recruiting T cells to sites of inflammation or tumor growth, which is vital for effective immune surveillance and response. Notably, MIG mRNA expression in human carcinoma line HSC-2 is induced by interferon-gamma, while other lines such as Ca9-22 and glioma line A172 do not express MIG mRNA, highlighting specific regulatory mechanisms. Additionally, elevated serum levels of MIG and CXCL10 in ocular sarcoidosis have been correlated with disease activity and angiotensin-converting enzyme levels, indicating potential as a biomarker for disease progression. The Gα i protein-coupled receptor CXCR3 binds MIG, which is released from intestinal epithelium, further emphasizing MIG′s role in mediating immune responses. MIG can inhibit responses induced by platelet activating factor and leukotriene B4, as well as block eotaxin-induced filamentous actin formation and chemoattraction, showcasing multifaceted involvement in immune regulation. As part of a larger family of chemokines, MIG interacts with a subset of seven transmembrane, G protein-coupled receptors, underscoring importance in the complex network of immune signaling.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MIG Antibody (A-9) References:

1. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma.  |  Ruehlmann, JM., et al. 2001. Cancer Res. 61: 8498-503. PMID: 11731434
2. The role of MIG/CXCL9 in cardiac allograft vasculopathy.  |  Yun, JJ., et al. 2002. Am J Pathol. 161: 1307-13. PMID: 12368204
3. Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects.  |  Wang, YQ., et al. 2003. Oncol Rep. 10: 909-13. PMID: 12792744
4. Constitutive nuclear factor kappaB activity is required to elicit interferon-gamma-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines.  |  Hiroi, M. and Ohmori, Y. 2003. Biochem J. 376: 393-402. PMID: 12946268
5. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection.  |  Belperio, JA., et al. 2003. J Immunol. 171: 4844-52. PMID: 14568964
6. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9).  |  Fulkerson, PC., et al. 2004. Proc Natl Acad Sci U S A. 101: 1987-92. PMID: 14769916
7. Identification, functional analysis and expression in a heterotopic heart transplant model of CXCL9 in the rat.  |  Mitsuhashi, N., et al. 2004. Immunology. 112: 87-93. PMID: 15096188
8. CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism.  |  Fulkerson, PC., et al. 2005. Blood. 106: 436-43. PMID: 15802529
9. The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts.  |  Kouroumalis, A., et al. 2005. J Immunol. 175: 5403-11. PMID: 16210647

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-MIG Antibody (A-9) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-MIG Antibody (A-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

MIG Antibody (A-9) Specifications

Alternate Product Name: MIG

Product Clone Name: A-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 32-53

Epitope Target: MIG

Epitope Species: human

Product Reactivity/Detection: MIG

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for MIG Antibody (A-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin